R&D/generics firms urge EU support for innovation, manufacturing
This article was originally published in Scrip
Executive Summary
The innovator and generics industries in Europe have teamed up to call for a more stable and predictable EU market environment that supports investment in innovative drugs while promoting "healthy and sustainable" competition in the form of generic and biosimilar medicines.